Clinical trial
Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone…
NCT00004482 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00004482 |
|---|---|
| Title | Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis |
| Lead sponsor | Mayo Clinic, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myocarditis, Giant Cell Myocarditis |
| Intervention type | Drug |
| Interventions | Cyclosporine, methylprednisolone, Muromonab-CD3, prednisone |
| Enrollment | 40 |
| Start date | Dec 1, 1999 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Oct 19, 1999 |
| Last update posted | Sep 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: